202 related articles for article (PubMed ID: 16546281)
1. Geometric stability of intracavitary pulsed dose rate brachytherapy monitored by in vivo rectal dosimetry.
Tanderup K; Christensen JJ; Granfeldt J; Lindegaard JC
Radiother Oncol; 2006 Apr; 79(1):87-93. PubMed ID: 16546281
[TBL] [Abstract][Full Text] [Related]
2. Point vs. volumetric bladder and rectal doses in combined intracavitary-interstitial high-dose-rate brachytherapy: correlation and comparison with published Vienna applicator data.
Yaparpalvi R; Mutyala S; Gorla GR; Butler J; Mah D; Garg MK; Kalnicki S
Brachytherapy; 2008; 7(4):336-42. PubMed ID: 18782683
[TBL] [Abstract][Full Text] [Related]
3. MRI-guided 3D optimization significantly improves DVH parameters of pulsed-dose-rate brachytherapy in locally advanced cervical cancer.
Lindegaard JC; Tanderup K; Nielsen SK; Haack S; Gelineck J
Int J Radiat Oncol Biol Phys; 2008 Jul; 71(3):756-64. PubMed ID: 18191335
[TBL] [Abstract][Full Text] [Related]
4. MRI-guided treatment-planning optimisation in intracavitary or combined intracavitary/interstitial PDR brachytherapy using tandem ovoid applicators in locally advanced cervical cancer.
Jürgenliemk-Schulz IM; Tersteeg RJ; Roesink JM; Bijmolt S; Nomden CN; Moerland MA; de Leeuw AA
Radiother Oncol; 2009 Nov; 93(2):322-30. PubMed ID: 19748695
[TBL] [Abstract][Full Text] [Related]
5. Low-dose-rate vs. high-dose-rate intracavitary brachytherapy for carcinoma of the cervix: The University of Alabama at Birmingham (UAB) experience.
Falkenberg E; Kim RY; Meleth S; De Los Santos J; Spencer S
Brachytherapy; 2006; 5(1):49-55. PubMed ID: 16563997
[TBL] [Abstract][Full Text] [Related]
6. Impact of "optimized" treatment planning for tandem and ring, and tandem and ovoids, using high dose rate brachytherapy for cervical cancer.
Noyes WR; Peters NE; Thomadsen BR; Fowler JF; Buchler DA; Stitt JA; Kinsella TJ
Int J Radiat Oncol Biol Phys; 1995 Jan; 31(1):79-86. PubMed ID: 7995771
[TBL] [Abstract][Full Text] [Related]
7. Clinical use of the Utrecht applicator for combined intracavitary/interstitial brachytherapy treatment in locally advanced cervical cancer.
Nomden CN; de Leeuw AA; Moerland MA; Roesink JM; Tersteeg RJ; Jürgenliemk-Schulz IM
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1424-30. PubMed ID: 21669505
[TBL] [Abstract][Full Text] [Related]
8. Retrospective dosimetric comparison of low-dose-rate and pulsed-dose-rate intracavitary brachytherapy using a tandem and mini-ovoids.
Mourtada F; Gifford KA; Berner PA; Horton JL; Price MJ; Lawyer AA; Eifel PJ
Med Dosim; 2007; 32(3):181-7. PubMed ID: 17707197
[TBL] [Abstract][Full Text] [Related]
9. Positional variability of a tandem applicator system in HDR brachytherapy for primary treatment of cervix cancer. Analysis of the anatomic pelvic position and comparison of the applicator positions during five insertions.
Wulf J; Popp K; Oppitz U; Baier K; Flentje M
Strahlenther Onkol; 2004 Apr; 180(4):216-24. PubMed ID: 15057432
[TBL] [Abstract][Full Text] [Related]
10. Applicator reconstruction and applicator shifts in 3D MR-based PDR brachytherapy of cervical cancer.
De Leeuw AA; Moerland MA; Nomden C; Tersteeg RH; Roesink JM; Jürgenliemk-Schulz IM
Radiother Oncol; 2009 Nov; 93(2):341-6. PubMed ID: 19515443
[TBL] [Abstract][Full Text] [Related]
11. Rectum dose analysis employing a multi-purpose brachytherapy phantom.
Huh H; Kim W; Loh JJ; Lee S; Kim CY; Lee S; Shin D; Shin D; Cho S; Jang J; Lim S; Cho KH; Kwon S; Kim S
Jpn J Clin Oncol; 2007 May; 37(5):391-8. PubMed ID: 17538010
[TBL] [Abstract][Full Text] [Related]
12. Radiotherapy doses at special reference points correlate with the outcome of cervical cancer therapy.
Yoshimura R; Hayashi K; Ayukawa F; Toda K; Iwata M; Oota S; Hoshi A; Wakatsuki M; Kurosaki H; Okazaki A; Shibuya H
Brachytherapy; 2008; 7(3):260-6. PubMed ID: 18579445
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact of computed tomography-based image-guided brachytherapy for cervix cancer using the tandem-ring applicator - the Addenbrooke's experience.
Tan LT; Coles CE; Hart C; Tait E
Clin Oncol (R Coll Radiol); 2009 Apr; 21(3):175-82. PubMed ID: 19101130
[TBL] [Abstract][Full Text] [Related]
14. [Rectal shielding for a Selectron-ring applicator system (HDR- and LDR-afterloading)].
Hetzel H; Kamleitner H; McCoy M; Frommhold H
Strahlenther Onkol; 1987 Dec; 163(12):782-6. PubMed ID: 3424077
[TBL] [Abstract][Full Text] [Related]
15. Time-resolved in vivo luminescence dosimetry for online error detection in pulsed dose-rate brachytherapy.
Andersen CE; Nielsen SK; Lindegaard JC; Tanderup K
Med Phys; 2009 Nov; 36(11):5033-43. PubMed ID: 19994514
[TBL] [Abstract][Full Text] [Related]
16. Transit dose contributions to intracavitary and interstitial PDR brachytherapy treatments.
Menon GV; Carlone MC; Sloboda RS
Phys Med Biol; 2008 Jul; 53(13):3447-62. PubMed ID: 18547912
[TBL] [Abstract][Full Text] [Related]
17. In-vivo dosimetry for gynaecological brachytherapy: physical and clinical considerations.
Waldhäusl C; Wambersie A; Pötter R; Georg D
Radiother Oncol; 2005 Dec; 77(3):310-7. PubMed ID: 16226818
[TBL] [Abstract][Full Text] [Related]
18. The Vienna applicator for combined intracavitary and interstitial brachytherapy of cervical cancer: design, application, treatment planning, and dosimetric results.
Kirisits C; Lang S; Dimopoulos J; Berger D; Georg D; Pötter R
Int J Radiat Oncol Biol Phys; 2006 Jun; 65(2):624-30. PubMed ID: 16690444
[TBL] [Abstract][Full Text] [Related]
19. [Measurement of the distance of the rectal mucosa from a gynecologic afterloading applicator based on the drop in performance of a cobalt-60-source].
Schrader R; Bahnsen J; Schrader D; Frischbier HJ
Strahlenther Onkol; 1994 Feb; 170(2):103-6. PubMed ID: 8108775
[TBL] [Abstract][Full Text] [Related]
20. Physics contributions and clinical outcome with 3D-MRI-based pulsed-dose-rate intracavitary brachytherapy in cervical cancer patients.
Chargari C; Magné N; Dumas I; Messai T; Vicenzi L; Gillion N; Morice P; Haie-Meder C
Int J Radiat Oncol Biol Phys; 2009 May; 74(1):133-9. PubMed ID: 18774656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
